21.05.2021 • News

KBR and Cummins Cooperate on Green Ammonia

US engineering and construction group KBR and US-based multinational Cummins, a manufacturer of engines, filtration and power generation products, have agreed a non-exclusive partnership on green ammonia.

Under the terms of a Memorandum of Understanding, KBR plans to integrate Cummins’ proton exchange membrane electrolysis technology into its own proprietary green ammonia solution, K-GreeN. The companies will also work to identify areas of deeper collaboration and specific opportunities worldwide.

“Collectively, our companies have the proprietary knowhow and expertise that will allow us to offer an integrated green ammonia solution to clients worldwide and help with achieving their corporate ESG [environmental, social and governance] initiatives,” said KBR president, technology, Doug Kelly.

Amy Davis, vice president and president of new power at Cummins, added: “We see great potential to deploy large scale electrolyzer solutions in green ammonia projects and working with KBR on an integrated solution provides value for our customers while enabling decarbonization.”

Green ammonia is seen as one of the most viable options to enable a transition from fossil fuels to renewables, KBR said. It can be used directly as a carbon-free fertilizer and as an energy carrier, for instance for transporting hydrogen, and also has potential as a climate-neutral shipping fuel.

Author: Elaine Burridge, Freelance Journalist

KBR and Cummins have agreed a non-exclusive partnership on green ammonia. KBR...
KBR and Cummins have agreed a non-exclusive partnership on green ammonia. KBR will integrate Cummins’ electrolysis technology into its own proprietary K-GreeN ammonia solution. The companies will also identify areas of deeper collaboration and specific opportunities worldwide. (c) KBR

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read